Acute Hepatitis C in HIV-infected Patients

Nina Kim, MD MSc
Assistant Professor of Medicine
University of Washington

February 14, 2013
Acute Hepatitis C

- Epidemiology: Recent Trends (among HIV+ MSM)
- Risk factors for acute HCV acquisition
- Screening
- Natural History & Clinical Features
- Case Definition: Challenges to Diagnosis
- To Treat or not to Treat?
- Management
Reported number of acute HCV cases U.S., 2000-2010
Hepatitis C Transmission

- HCV most efficiently transmitted parenterally
- Sexual transmission in general population considered rare
  - Among cohort of 895 heterosexual HCV-serodiscordant couples, only 3 transmissions occurred → incidence 0.37/1000 person-years
  - Strain analysis did not support sexual transmission
- Barrier protection not mandated for HCV prevention
- Historically, HCV prevalence among HIV-infected tracked closely with injection drug use (IDU)
  - 1-7% among MSM without IDU versus 25-50% among MSM + IDU

Rising Hepatitis C Incidence among HIV-infected MSM

• 2004-2005: Increased HCV incidence in multiple countries in Europe → US/Canada, Australia, Asia
  - Netherlands – HCV prevalence among HIV-infected MSM rose from 1-4% in 2000 to 21% in 2008

• Many of these cohorts reported low rates of IDU

• Phylogenetic comparisons show HCV transmission clusters among sexual networks of MSM

• Alarming patterns of reinfection occurring among those patients who clear, either spontaneously or with tx.

Ingiliz, CROI 2012, Abstract 752.
World Hepatitis Day — July 28, 2011

July 28, 2011, marks the first official World Hepatitis Day established by the World Health Organization (WHO). CDC joins with WHO to call for a renewed focus on diagnosis, treatment, and prevention of viral hepatitis.

Sexual Transmission of Hepatitis C Virus Among HIV-Infected Men Who Have Sex with Men — New York City, 2005–2010

CDC’s National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
Acute HCV in HIV-infected MSM in New York City

- 2005-2010, total of 74 HIV-infected MSM with recently acquired HCV referred to Mt Sinai Medical Center
- None had reported hx IDU
- Phylogenetic analysis of HCV strains revealed five clusters of closely-related HCV variants
- Clinical Features of 74 men:
  - Mean CD4 count 483 cells/mm$^3$. Median age 39 years.
  - 60 (81%) asymptomatic – new HCV infection detected solely by new ALT elevation.
  - 14 (19%) had jaundice.
  - Median peak ALT level 665 U/L (range 72-5,291 U/L).
Acute HCV in HIV-infected MSM in New York City

- Cases and matched controls (also HIV+ MSM but no HCV)
- Completed self-administered surveys re sexual practices & drug-use behaviors during preceding 12 months.
- Multivariate analyses:
  - Receptive anal intercourse with no condom & with ejaculation of partner (adjusted odds ratio [aOR] = 23)
  - Sex while using methamphetamine (aOR = 28.6) → most strongly associated with HCV acquisition
Risk Factors for HCV Acquisition among HIV+ MSM

• Behavioral Factors:
  - “Serosorting” → concordant unprotected anal receptive intercourse
  - Mucosally traumatic sex practices: group sex, use of sex toys, fisting
  - Use of drugs during sex: methamphetamine (not IDU)

• Biologic Factors:
  - HIV infection: higher serum HCV viral levels
  - Sexually transmitted infections
    • Syphilis
    • Lymphogranuloma venereum proctitis
    • Gonorrhea, Chlamydia

Screening High-risk Patients
Quarterly ALT

• Urban HIV care center: a third of all HIV-infected patients were HCV-coinfected
  - 34% of HCV-HIV patients reported MSM as primary risk factor
  - 25% reported IDU; 2% both

• Completed survey re risk behaviors & perceptions of risk

• HCV-susceptible high-risk patients screened with q3 mon ALT:
  - MSM with unprotected traumatic anal sex, STI, or stimulant/drug use
  - MSM with >5 sex partners within prior 6 months
  - MSM with HCV-infected partner
  - Intranasal or injection drug

• Elevated ALT (>45 U/L or >1.5 X baseline) triggered HCV RNA testing (pooled for uninsured patients)

Screening High-risk Patients
Quarterly ALT

- Majority (54%) of MSM did not perceive traumatic sexual or drug practices increased their risk for HCV
- Unprotected sex often occurred w/ drugs or alcohol
- Decent rollout: 88% participants had at least one ALT in 9-month follow-up.
- 2% annual incidence (n=1 among 58 participants)

Natural History of Acute HCV Infection

- Incubation period = 10-14 weeks.
  - Clinical illness occurs a mean 7 weeks from exposure
- HCV RNA (+) as early as 1 week post-infection.
- HCV Ab seroconversion detected 2-6 months post-infection.
- Only ~10-20% clinically ill – rarely fulminant.
- ALT typically 400-1000 U/L; Bilirubin rarely >12 mg/dl.
- Spontaneous clearance – estimated 20-25%, may be lower in HIV-infected.

Diagnosis of Acute Hepatitis C

- Diagnosis of acute HCV can be challenging:
  - Most cases asymptomatic
  - No reliable or specific IgM-based HCV antibody test

- CDC case definition:
  - Acute illness compatible w/ hepatitis or serum ALT >400 AND
  - Antibodies to HCV (either by EIA or RIBA) or
  - HCV RNA positive by nucleic acid testing AND
  - Exclusion of acute HAV or HBV – negative anti-HAV IgM and anti-HBV core IgM

- HCV RNA levels can fluctuate widely in early infection.

- Seroconversion can be delayed
  - About 2/3 (+)Ab by 3 months
  - 5% can still be Ab negative by 12 months
Spontaneous Clearance after Acute Infection
HCV Persistence after Acute Infection

[Graph showing HCV infection progression over weeks with markers for HCV RNA, ALT, and Anti-HCV, indicating +/- Symptoms.]
To Treat or not to Treat
Predictors of Spontaneous HCV Clearance

- Higher CD4 cell counts
- Lower peak HCV RNA levels
- Rapid early decline in HCV viral level
- High ALT
- Presence of jaundice
- Female gender
- Younger age
- Non-black race
- Coinfection with chronic hep B (+HBsAg)
- *IL28B* CC homozygous genotype
HCV Clearance by *IL28B* Genotype

When to Treat? Acute Hepatitis C

- Treatment of acute HCV shown to reduce risk of chronic persistent infection with improved rates of SVR compared with established infection:
  - SVR 30% for genotype 1 in chronic HCV with dual therapy vs
  - SVR 60-80% for genotype 1* with dual therapy in acute HCV

- Weigh the decision to treat carefully:
  - To avoid unnecessary therapy in those who will clear and
  - To achieve highest possible SVR for those who will not

(* SVR >90% for genotype 2 or 3)
When to Treat?
Viral Monitoring & Timing

• Important to monitor HCV RNA q4 weeks in acute HCV

• Indications for treatment:
  - Absence of a $2 \log_{10}$ drop in HCV RNA x 4 weeks
  - Persistent HCV viremia at 12 weeks

• Most experts agree best to wait at least 8-12 weeks before starting therapy for acute HCV

• A short delay of 12 weeks is unlikely to compromise SVR rates but a delay of >12 months halves the likelihood of SVR

Optimal regimen remains unclear

Most studies of acute HCV are case series, small cohorts and use both peg-interferon & ribavirin (wt-based or fixed)

Duration also unclear
- Studies heterogeneous with duration ranging from 12 to 48 wks (most of them 24 wks)
- Our clinic opts for peginterferon + ribavirin of 24 weeks duration esp. for patients who achieve a rapid virologic response
- Consider 48 weeks in patients with suboptimal early viral response
Acute Hepatitis C
Role of Direct-acting Antivirals (DAAs)

• Remains to be seen…

• Current DAAs (telaprevir, boceprevir): no data in acute HCV

• DAAs to revolutionize HCV management for both acute & chronic infection

• Real potential for
  - All oral (IFN-free) regimens
  - Short duration courses (<12 weeks?)*
  - Enhanced tolerability
  - High efficacy (>90% SVR)
Hepatitis Web Study

Featuring
Interactive, case-based modules with free CE credits
Slide library with presentations for downloading
A glossary of definitions and terms

Editors
Jeanne Marrazzo, MD, MPH
Professor of Medicine
Division of Infectious Diseases
University of Washington

David H. Spach, MD
Professor of Medicine
Division of Infectious Diseases
University of Washington

H. Nina Kim, MD
Assistant Professor of Medicine
Division of Infectious Diseases
University of Washington

Funded by the Centers for Disease Control and Prevention

www.hepwebstudy.org
Thanks!